The medicine, Lenmeldy (atidarsagene autotemcel), is a one-time infusion made from the patient’s hematopoietic stem cells and modified copies of the arylsulfatase A gene, the FDA said. The genetic disease, which is caused by an ARSA gene deficiency, manifests into the loss of motor and cognitive function, and early death.
In a trial, 37 children received Lenmeldy and experienced a significant reduction in the risk of severe motor impairment and death compared to untreated children.
At 5 years old, 71% of treated children could walk without assistance. All study participants who had pre-symptomatic late infantile MLD were alive at 6 years old, compared to 58% of children in the control group.
Before treatment, patients must undergo high-dose chemotherapy. The drug approval was given to Orchard Therapeutics.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
